Commercial feasibility of engineered neural tissue

工程神经组织的商业可行性

• 批准号: 133342
• 金额: $ 12.74万
• 依托单位: GLIALIGN LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=133342
• 关键词: Commercial; feasibility; engineered; neural; tissue

Peripheral nerve injury is debilitating, causing loss of feeling and movement and in some cases long-term pain. Nerves can be repaired surgically to enable regeneration to occur, but often the injury results in a large gap which needs to be bridged. Currently the best way to repair large gaps is to use a nerve graft, which involves taking a healthy nerve section from elsewhere in the patient's body, which is limited in terms of the amount of tissue available and which causes additional loss of function at the donor site. Glialign is a new company set up to develop a solution to this problem. Our approach combines tissue engineering technology with therapeutic cells in order to build living replacement nerve tissue which mimics the structure and function of a natural nerve graft (Engineered Neural Tissue, EngNT). By using cells and materials that are safe to implant into any person without immune rejection, EngNT has the potential to be an 'off the shelf' product, immediately available for nerve repair whenever and wherever it is required. This project will evaluate the clinical and commercial feasibility of the technology through preclinical testing and development of a strong business case, leading to future regulatory and manufacturing development and clinical trials.

周围神经损伤使人虚弱，导致感觉和活动的丧失，在某些情况下还会长期疼痛。神经可以通过手术修复，以使再生发生，但通常损伤会导致巨大的缺口，需要弥合。目前修复大间隙的最好方法是使用神经移植，这涉及从患者身体其他部位取出健康的神经部分，可用组织数量有限，并会导致供体部位额外的功能丧失。Glialign是一家新成立的公司，目的是为这一问题开发解决方案。我们的方法将组织工程技术与治疗细胞相结合，以构建模仿自然神经移植(工程神经组织，EngNT)的结构和功能的活的替代神经组织。通过使用安全的细胞和材料植入任何人体内而没有免疫排斥反应，EngNT有可能成为一种“现成”的产品，无论何时何地都可以立即用于神经修复。该项目将通过临床前测试和开发强大的商业案例来评估该技术的临床和商业可行性，从而导致未来的监管和制造开发和临床试验。